News Focus
News Focus
icon url

DewDiligence

10/04/16 7:44 PM

#204918 RE: Whalatane #204914

OCRX—Further to this discussion, the outcome of the NIH-sponsored phase-2a trial in ALF is not what I consider a major market-moving event. ALF is not an indication where I expect OCR-002 to be a standout.